HB0025 is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is Shanghai Huaota Biopharmaceutical Co., Ltd (1). The most-studied condition is Non Squamous Non-small Cell Lung Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
NCT07383116 · ClinicalTrials.gov ↗ · Non Squamous Non-small Cell Lung Cancer
|
Phase 3 | Not yet open | Shanghai Huaota Biopharmaceutical Co., Ltd. | China |
|
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT07376629 · ClinicalTrials.gov ↗ · TNBC
|
Phase 2 | By invitation | Huabo Biopharm Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Huaota Biopharmaceutical Co., Ltd. | 1 |
| Huabo Biopharm Co., Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name HB0025 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Shanghai Huaota Biopharmaceutical Co., Ltd (1) and Huabo Biopharm Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how HB0025 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how HB0025 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists HB0025 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.